These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Prognostic prediction in patients with metastatic renal cell carcinoma treated with sorafenib based on expression levels of potential molecular markers in radical nephrectomy specimens. Kusuda Y; Miyake H; Behnsawy HM; Fukuhara T; Inoue TA; Fujisawa M Urol Oncol; 2013 Jan; 31(1):42-50. PubMed ID: 21396851 [TBL] [Abstract][Full Text] [Related]
23. Cytokine therapy: a standard of care for metastatic renal cell carcinoma? Hutson TE; Quinn DI Clin Genitourin Cancer; 2005 Dec; 4(3):181-6. PubMed ID: 16425986 [TBL] [Abstract][Full Text] [Related]
24. Imaging the clear cell renal cell carcinoma proteome. Morgan TM; Seeley EH; Fadare O; Caprioli RM; Clark PE J Urol; 2013 Mar; 189(3):1097-103. PubMed ID: 23009866 [TBL] [Abstract][Full Text] [Related]
25. C-reactive protein: a biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy. Casamassima A; Picciariello M; Quaranta M; Berardino R; Ranieri C; Paradiso A; Lorusso V; Guida M J Urol; 2005 Jan; 173(1):52-5. PubMed ID: 15592024 [TBL] [Abstract][Full Text] [Related]
27. High-dose interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma: still the standard. Dutcher JP Oncology (Williston Park); 2011 Apr; 25(5):427-8. PubMed ID: 21710841 [No Abstract] [Full Text] [Related]
28. Expression level of vascular endothelial growth factor receptor-2 in radical nephrectomy specimens as a prognostic predictor in patients with metastatic renal cell carcinoma treated with sunitinib. Terakawa T; Miyake H; Kusuda Y; Fujisawa M Urol Oncol; 2013 May; 31(4):493-8. PubMed ID: 21478036 [TBL] [Abstract][Full Text] [Related]
29. Serum interleukin-6 levels in metastatic renal cell carcinoma before treatment with interleukin-2 correlates with paraneoplastic syndromes but not patient survival. Walther MM; Johnson B; Culley D; Shah R; Weber J; Venzon D; Yang JC; Linehan WM; Rosenberg SA J Urol; 1998 Mar; 159(3):718-22. PubMed ID: 9474133 [TBL] [Abstract][Full Text] [Related]
30. Characterization of tumor specimens for a targeted therapy in metastatic renal cell carcinoma patients. Raspollini MR Curr Oncol Rep; 2007 Sep; 9(5):331. PubMed ID: 17706159 [No Abstract] [Full Text] [Related]
31. Predicting survival of patients with metastatic renal cell carcinoma. Motzer RJ; Mazumdar M Urologe A; 2004 Sep; 43 Suppl 3():S135-6. PubMed ID: 15148574 [TBL] [Abstract][Full Text] [Related]
32. Prognostic value of CC-chemokine receptor seven expression in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitor. Xia Y; Liu L; Xiong Y; Bai Q; Wang J; Xi W; Qu Y; Xu J; Guo J BMC Cancer; 2017 Jan; 17(1):70. PubMed ID: 28114889 [TBL] [Abstract][Full Text] [Related]
33. Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study. Voss MH; Reising A; Cheng Y; Patel P; Marker M; Kuo F; Chan TA; Choueiri TK; Hsieh JJ; Hakimi AA; Motzer RJ Lancet Oncol; 2018 Dec; 19(12):1688-1698. PubMed ID: 30416077 [TBL] [Abstract][Full Text] [Related]
34. The Role of High Dose Interleukin-2 in the Era of Targeted Therapy. Gills J; Parker WP; Pate S; Niu S; Van Veldhuizen P; Mirza M; Holzbeierlein JM; Lee EK J Urol; 2017 Sep; 198(3):538-545. PubMed ID: 28288839 [TBL] [Abstract][Full Text] [Related]
35. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma. Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106 [TBL] [Abstract][Full Text] [Related]
36. Metastatic renal cell carcinoma to the bladder 12 years after radical nephrectomy. Shiraishi K; Mohri J; Inoue R; Kamiryo Y Int J Urol; 2003 Aug; 10(8):453-5. PubMed ID: 12887369 [TBL] [Abstract][Full Text] [Related]
37. Characterizing the impact of lymph node metastases on the survival outcome for metastatic renal cell carcinoma patients treated with targeted therapies. Kroeger N; Pantuck AJ; Wells JC; Lawrence N; Broom R; Kim JJ; Srinivas S; Yim J; Bjarnason GA; Templeton A; Knox J; Bernstein E; Smoragiewicz M; Lee J; Rini BI; Vaishampayan UN; Wood LA; Beuselinck B; Donskov F; Choueiri TK; Heng DY Eur Urol; 2015 Sep; 68(3):506-15. PubMed ID: 25524810 [TBL] [Abstract][Full Text] [Related]